Compositions and methods for treating HCV
This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
1. A pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B,
wherein therapeutic agent A is compound A or a salt thereof:
wherein therapeutic agent B is compound B or a salt thereof:
wherein the molar ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000.
2. The pharmaceutical composition of claim 1 , wherein the amount of therapeutic agent B is about 200 mg.
3. The pharmaceutical composition of claim 1 , wherein the amount of therapeutic agent A is from about 5 mg to about 200 mg.
4. The pharmaceutical composition of claim 1 , wherein the composition further comprises one or more additional therapeutic agents.
5. The pharmaceutical composition of claim 4 , wherein the one or more additional therapeutic agents include an HCV protease inhibitor.
6. The pharmaceutical composition of claim 5 , wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor.
7. The pharmaceutical composition of claim 1 , further comprising an HCV protease inhibitor and a cytochrome P-450 inhibitor.
8. The pharmaceutical composition of claim 7 , wherein the cytochrome P-450 inhibitor is ritonavir.
9. The pharmaceutical composition of claim 1 , wherein therapeutic agent B is a sodium salt of compound B.